Literature DB >> 34177306

Favipiravir Experience in Covid-19 Positive Myasthenia Gravis Patients.

Recep Yevgi1, Nuray Bilge1, Fatma Şimşek1.   

Abstract

Entities:  

Year:  2021        PMID： 34177306      PMCID： PMC8184048          DOI： 10.5152/eurasianjmed.2021.20364

Source DB:  PubMed          Journal:  Eurasian J Med        ISSN： 1308-8734


× No keyword cloud information.
  3 in total

Review 1.  Myasthenia gravis and infectious disease.

Authors:  Nils Erik Gilhus; Fredrik Romi; Yu Hong; Geir Olve Skeie
Journal:  J Neurol       Date:  2018-01-25       Impact factor: 4.849

2.  Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network.

Authors:  G Solé; E Salort-Campana; Y Pereon; T Stojkovic; K Wahbi; P Cintas; D Adams; P Laforet; V Tiffreau; I Desguerre; L I Pisella; A Molon; S Attarian
Journal:  Rev Neurol (Paris)       Date:  2020-04-20       Impact factor: 2.607

3.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.

Authors:  Philippe Gautret; Jean-Christophe Lagier; Philippe Parola; Van Thuan Hoang; Line Meddeb; Morgane Mailhe; Barbara Doudier; Johan Courjon; Valérie Giordanengo; Vera Esteves Vieira; Hervé Tissot Dupont; Stéphane Honoré; Philippe Colson; Eric Chabrière; Bernard La Scola; Jean-Marc Rolain; Philippe Brouqui; Didier Raoult
Journal:  Int J Antimicrob Agents       Date:  2020-03-20       Impact factor: 5.283
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.